How should fondaparinux be used in non‑ST‑segment elevation acute coronary syndrome, including dose, timing, renal function limits, and contraindications such as percutaneous coronary intervention?

Fondaparinux for Non-ST-Elevation Acute Coronary Syndrome

Fondaparinux 2.5 mg subcutaneously once daily is an effective anticoagulant option for NSTE-ACS with superior bleeding safety compared to enoxaparin, but it is absolutely contraindicated if creatinine clearance is <30 mL/min and should NOT be used as the sole anticoagulant if PCI is planned due to catheter thrombosis risk. 1

Dosing and Administration

Standard dose: 2.5 mg subcutaneously once daily, regardless of body weight 1

• Administer as initial therapy at diagnosis
• Continue until revascularization or hospital discharge
• No dose adjustment needed for body weight in ACS (unlike VTE treatment) 2
• Subcutaneous injection only—never intramuscular 2

Critical Contraindications

Absolute Contraindications:

• Creatinine clearance <30 mL/min 1, 2
• Active major bleeding 2
• Body weight <50 kg (for prophylaxis only, not ACS) 2
• Bacterial endocarditis 2

Relative Contraindication - PCI:

Fondaparinux should NOT be used to support PCI because of catheter thrombosis risk 1

• In OASIS-5, catheter thrombus occurred in 0.9% with fondaparinux vs 0.3% with enoxaparin 1
• If a patient on fondaparinux requires PCI, add a single bolus of unfractionated heparin at the time of catheterization 3
• This is the most important clinical pitfall to avoid

When to Choose Fondaparinux

Fondaparinux is the preferred anticoagulant when:

• Conservative (non-invasive) management strategy is planned 3
• Patient has high bleeding risk 1, 4
• Renal dysfunction present (but CrCl ≥30 mL/min) 5
• Logistical constraints delay PCI transfer beyond required timeframe 3

The 2025 ACC/AHA guidelines specifically state: "In cases of medical treatment or logistical constraints for transferring the patient to PCI within the required time frame, fondaparinux is recommended" 3

Evidence Base and Clinical Benefits

Fondaparinux demonstrated similar efficacy to enoxaparin for ischemic events but 50% reduction in major bleeding in the OASIS-5 trial 1, 6. This bleeding benefit translates to mortality reduction and superior net clinical benefit 7, 4.

Key advantages:

• Once-daily dosing without monitoring 8
• Predictable pharmacokinetics with 100% bioavailability 9
• No heparin-induced thrombocytopenia risk 8
• Greatest benefit in patients with renal dysfunction (CrCl ≥30 but <58 mL/min) 5

Renal Function Considerations

• CrCl ≥30 mL/min: Standard 2.5 mg daily dose 1
• CrCl <30 mL/min: Absolutely contraindicated 1, 2
• Patients with moderate renal impairment (CrCl 30-58 mL/min) derive the greatest relative benefit from fondaparinux over enoxaparin due to marked bleeding reduction 5

Clinical Algorithm for Anticoagulant Selection in NSTE-ACS

Step 1: Check creatinine clearance

• If CrCl <30 mL/min → Do NOT use fondaparinux; choose UFH or adjusted-dose enoxaparin 1

Step 2: Determine revascularization strategy

• Early invasive strategy (PCI planned) → Prefer enoxaparin or UFH over fondaparinux 1
  • If fondaparinux already started, add UFH bolus at PCI 3
• Conservative or delayed invasive strategy → Fondaparinux is preferred 3

Step 3: Assess bleeding risk

• High bleeding risk + conservative strategy → Strong preference for fondaparinux 4

Common Pitfalls to Avoid

1. Using fondaparinux as sole anticoagulant during PCI - Always add UFH bolus if PCI becomes necessary 1, 3
2. Administering to patients with severe renal impairment - Verify CrCl ≥30 mL/min before first dose 1, 2
3. Expelling air bubble from prefilled syringe - This causes drug loss; inject with air bubble present 2
4. Switching between anticoagulants - Crossover between fondaparinux and other agents should be avoided except when adding UFH for PCI 3

Duration of Therapy

Continue fondaparinux until:

• Revascularization is performed, OR
• Hospital discharge, OR
• Clinical stabilization achieved

Typical duration is 5-9 days in clinical trials 1, 2

The 2021 ESC guidelines give fondaparinux a Class I, Level B recommendation for medical management when PCI transfer is delayed 3, while the 2025 ACC/AHA guidelines provide detailed dosing tables positioning fondaparinux as a standard option with specific caveats 1.